CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related ...

CRISPR-generated knockout mutants reveal that the highly expressed, symbiosome-localized nodulin NOD25 is dispensable for ...

A new Pediatric Research commentary argues that insurance coverage and reimbursement policy, not the underlying science, now ...

For decades, scientists have believed that a protein called interferon tau (IFNT) is indispensable for pregnancy in cattle.

DNA typewriter maps mouse embryo development to reveal disease origins Barcode trail tracks cell family trees to pinpoint ...

Fintel reports that on October 8, 2026, Wells Fargo upgraded their outlook for Editas Medicine (NASDAQGS:EDIT) (LSE:0IFK) from Equal-Weight to Overweight. Editas Medicine, Inc., based in the United ...

Anthropic says its AI agents identified an unusual DNA structure in bacteriophages that resembles CRISPR-Cas9. Its function ...

Editas Medicine, Inc. announced it had received approval to initiate the Phase 1/2 Strive? clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company ...

LMU researchers challenge a decades-old model: genetically modified embryos lacking interferon tau can establish pregnancies and develop into healthy ...